查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844421

癌症生物療法市場按療法類型、用途、給藥途徑、最終用戶和分銷管道分類－2025-2032年全球預測

Cancer Biological Therapy Market by Therapy Type, Application, Administration Route, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症生物療法市場將成長至 1,785 億美元，複合年成長率為 11.93%。

主要市場統計數據
基準年 2024 724.2億美元
預計年份：2025年 812.5億美元
預測年份：2032年 1785億美元
複合年成長率 (%) 11.93%

透過策略規劃，整合科學突破、營運挑戰和相關人員的優先事項，塑造現代癌症生物治療格局。

癌症生物療法已進入一個轉型期，其特徵是分子科學、轉化平台和以患者為中心的護理管道的融合。免疫腫瘤學、工程細胞療法和標靶生技藥品的發展正在重塑臨床實踐和產業營運，促使相關人員重新評估研發、生產和商業化等各個環節的策略重點。本次研討會將整理當前的產業格局，重點在於影響策略決策的科學曲折點、供應鏈現狀以及相關人員的期望。

近期趨勢表明，開發商和醫療服務提供者正從概念驗證轉向可擴展的臨床項目和整合式醫療模式。因此，臨床團隊和管理人員必須權衡長期科學研究機會與短期營運限制。在此背景下，研究機構、合約研究組織和商業生產商正加強合作，以降低後期研發風險，並確保產品順利過渡到更廣泛的患者群體。因此，領導者們正優先考慮平台穩健性、生產靈活性和循證醫學證據的生成，以支持與監管機構和支付方的溝通。

本執行摘要的其餘部分深入分析了塑造治療創新格局的變革性轉變、影響供應鏈的貿易政策逆風、區域動態、領先企業的舉措，並為行業領導者提供了切實可行的建議。這些要素共同構成了一份簡潔明了的綜合報告，旨在幫助企業在這個快速發展的領域制定明智的策略並合理分配資源。

確定關鍵的科學、生產和支付方主導的變革性變化，這些變化將從根本上改變新型生技藥品的開發、生產和報銷方式。

癌症生物治療領域正經歷一系列變革性的再形成，這些轉變貫穿整個價值鏈，從實驗室研究到臨床應用。高保真度分子譜分析和新型抗原發現工具拓展了標靶範圍，使得疫苗、工程細胞產品和腫瘤治療平台的設計更加精準。載體設計、基因編輯精準度與免疫調節構建體的改進，共同提升了新型生技藥品的治療指數。隨著轉化路徑的日趨成熟，檢測設計也變得更加靈活，並以生物標記主導，加速訊號檢測，並有助於更早做出是否繼續治療的決策。

同時，製造技術的創新正在提升複雜治療方法的可行性。模組化和封閉式系統製造方法降低了污染風險，並支援分散式生產模式；而一次性使用和製程密集技術則提高了細胞和基因療法的生產效率。這些營運優勢正在推動新的商業化模式，例如中心輻射式和混合型履約網路，從而在不影響品質的前提下，使患者能夠更便捷地獲得專業治療方法。

從市場角度來看，支付方參與和健康技術評估流程正在不斷發展，以適應持久療效和治療潛力。真實世界證據的生成和結果導向的合約正成為報銷討論的核心，促使申辦方將長期追蹤和衛生經濟學納入早期研發規劃。總而言之，這些變化正在重新定義科學機會與永續的患者可及性和持久的商業性價值之間的關聯。

分析2025年貿易政策調整將如何影響整個生態系中的生物治療供應鏈、生產地點選擇和策略採購因應措施。

2025年新關稅和貿易措施的實施，為全球生物治療藥物供應鏈帶來了更多複雜性。隨著製造商重新評估其供應商佈局和非連續庫存，原料採購、關鍵試劑供應以及專用設備的進口都面臨新的審查。為此，許多相關人員正在加快供應商多元化和近岸外包策略，以維持供應的連續性並降低關稅波動帶來的風險。

除了直接投入成本外，關稅也影響物流規劃和資本配置。贊助商和製造外包正在重新評估高價值製造資產的選址，以及集中規模和區域韌性之間的權衡。因此，企業正在增加對本地監管專業知識和國內品質體系的投資，以簡化跨境轉移流程，並減少與海關和合規相關的行政摩擦。

策略因應措施也包括加強價值鏈各環節的合作。長期供應商協議、對區域生產能力的共同投資以及關鍵上游能力的垂直整合，已成為穩定成本和進度的更可行途徑。在政策層面，業界正積極遊說貿易當局，並參與多邊論壇，以澄清關稅表，並爭取符合許多生物療法公共衛生性質的豁免。這些措施旨在確保患者能夠持續獲得所需藥物，同時積極管控商業性和營運風險。

揭示不同治療方式、適應症、給藥途徑、最終用戶和分銷管道的細微策略影響，以明確研發和商業化選擇。

基於細分市場的觀點揭示了生物療法領域中臨床、營運和商業差異最為顯著的細分市場。依治療方法類型分類，市場涵蓋癌症治療方法、CAR-T細胞療法、細胞激素療法、基因療法、單株抗體和溶瘤病毒療法等。單株抗體進一步細分為嵌合體、人源抗體、人源化抗體和鼠源抗體，每種抗體都有不同的研發考量和臨床應用領域。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用患者特異性腫瘤特徵的個人化新抗原疫苗的出現，提高了免疫反應。
  • 快速將基因編輯CAR-T療法引入臨床，並最佳化安全開關以最大限度減少細胞激素釋放症候群。
  • 擴展我們的溶瘤病毒平台，並將其與免疫查核點抑制劑聯合使用，以實現協同腫瘤根除
  • 針對免疫查核點和共刺激通道的多特異性抗體形式的進步提高了療效
  • 整合人工智慧驅動的生物標記發現技術，以預測患者對癌症生技藥品的反應並縮短研發週期
  • 人們對能夠重塑腫瘤微環境並提高治療反應率的微生物來源免疫調節劑越來越感興趣。
  • 市售的同種異體NK細胞療法的出現，旨在實現持續活性並降低移植物抗宿主風險。
  • 開發具有可控半衰期延長的雙特異性T細胞銜接器，以提高安全性和給藥靈活性。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章：按治療類型分類的癌症生物療法市場

  • 癌症疫苗
  • CAR-T細胞療法
  • 細胞激素療法
  • 基因治療
  • 單株抗體
    • 嵌合體
    • 人類
    • 人性化
    • 老鼠
  • 溶瘤病毒療法

第9章 按應用分類的癌症生物療法市場

  • 乳癌
  • 大腸直腸癌
  • 造血系統惡性腫瘤
  • 黑色素瘤
  • 非小細胞肺癌
  • 攝護腺癌

第10章 依給藥途徑分類的癌症生物療法市場

  • 肌肉內注射
  • 靜脈
  • 口服
  • 皮下

第11章 按最終用戶分類的癌症生物療法市場

  • 門診治療中心
  • 家庭醫療保健
  • 醫院
  • 研究所
  • 專科診所

第12章 癌症生物療法市場按分銷管道分類

  • 直銷
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 各地區癌症生物療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症生物療法市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國癌症生物療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Merck & Co. Inc
    • Bristol-Myers Squibb Company
    • Novartis International AG
    • Amgen Inc
    • Pfizer Inc
    • Johnson & Johnson
    • AstraZeneca plc
    • Gilead Sciences, Inc
    • AbbVie Inc
Product Code: MRR-B72AD18D0F9C

The Cancer Biological Therapy Market is projected to grow by USD 178.50 billion at a CAGR of 11.93% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 72.42 billion
Estimated Year [2025] USD 81.25 billion
Forecast Year [2032] USD 178.50 billion
CAGR (%) 11.93%

Framing the contemporary cancer biological therapy landscape by synthesizing scientific breakthroughs, operational challenges, and stakeholder priorities for strategic planning

Cancer biological therapy has entered a transitional phase defined by convergence between molecular science, translational platforms, and patient-centered care pathways. Advances in immuno-oncology, engineered cell therapies, and targeted biologics have reshaped both clinical practice and industrial operations, prompting stakeholders to re-evaluate strategic priorities across research, development, manufacturing, and commercialization. This introduction frames the contemporary landscape by highlighting the scientific inflection points, supply chain realities, and stakeholder expectations that together drive strategic decision-making.

Over recent years, developers and care providers have moved from proof-of-concept demonstrations toward scalable clinical programs and integrated care models. As a result, clinical teams and executives must reconcile long-term scientific opportunity with near-term operational constraints. In this context, research institutions, contract development organizations, and commercial manufacturers are collaborating more closely to de-risk late-stage development and enable smoother transitions to wider patient access. Consequently, leaders are prioritizing platform robustness, manufacturing agility, and evidence generation that supports regulatory and payer engagement.

The remainder of this executive summary is structured to present the transformative shifts shaping therapeutic innovation, the trade policy headwinds influencing supply chains, segmentation-informed strategic insights, regional dynamics, leading corporate behaviors, and pragmatic recommendations for industry leaders. Together, these elements provide a concise synthesis that supports informed strategy-setting and resource prioritization in a rapidly evolving field.

Identifying the pivotal scientific, manufacturing, and payer-driven transformations fundamentally altering how novel cancer biologics are developed, produced, and reimbursed

The field of cancer biological therapy is being reshaped by a set of transformative shifts that extend from bench to bedside and across value chains. High-fidelity molecular profiling and new antigen discovery tools have expanded the target space, enabling more precise design of vaccines, engineered cell products, and oncolytic platforms. This scientific momentum is complemented by enhancements in vector design, gene editing accuracy, and immunomodulatory constructs, which collectively increase the therapeutic index of novel biologics. As translational pathways mature, trial designs have become more adaptive and biomarker-driven, accelerating signal detection and enabling earlier go/no-go decisions.

Concurrently, manufacturing innovations are improving the feasibility of complex modalities. Modular and closed-system manufacturing approaches reduce contamination risk and support decentralized production models, while single-use technologies and process intensification techniques enhance throughput for cell- and gene-based therapeutics. These operational gains are fostering new commercialization approaches, including hub-and-spoke and hybrid fulfillment networks that bring specialized therapies closer to patients without compromising quality.

From a market perspective, payer engagement and health technology assessment processes are evolving to accommodate durable responses and curative potential. Real-world evidence generation and outcomes-based contracting are becoming central to reimbursement discussions, prompting sponsors to integrate long-term follow-up and health economics into early development plans. Taken together, these shifts are redefining how scientific opportunity is translated into sustainable patient access and lasting commercial value.

Analyzing how 2025 trade policy adjustments influence biological therapy supply chains, manufacturing placement decisions, and strategic sourcing responses across the ecosystem

The introduction of new tariffs and trade measures in the United States in 2025 has introduced additional complexity into global supply chains for biological therapeutics. Raw material sourcing, critical reagent availability, and the importation of specialized equipment face renewed scrutiny as manufacturers reassess vendor footprints and contingency inventories. In response, many stakeholders are accelerating supplier diversification and nearshoring strategies to preserve continuity of supply and to mitigate exposure to tariff volatility.

Beyond direct input costs, tariffs have influenced logistical planning and capital allocation. Sponsors and contract manufacturers are reevaluating the placement of high-value manufacturing assets and the trade-offs between centralized scale and regionalized resilience. As a consequence, firms are increasing investment in local regulatory expertise and in-country quality systems to streamline cross-border transfers and reduce the administrative friction associated with customs and compliance.

Strategic responses also include enhanced collaboration across the value chain. Long-term supplier agreements, co-investment in regional production capacity, and vertical integration of critical upstream capabilities have become more pragmatic ways to stabilize costs and timelines. At the policy level, industry engagement with trade authorities and participation in multilateral forums are being deployed to clarify tariff schedules and to advocate for exemptions that reflect the public health nature of many biological therapies. These combined measures aim to ensure that patient access is preserved while commercial and operational risks are actively managed.

Revealing nuanced strategic implications across modality, indication, administration route, end user, and distribution axes to sharpen development and commercialization choices

A segmentation-informed perspective clarifies where clinical, operational, and commercial differentiation is most pronounced across the biological therapy landscape. Based on therapy type, the market encompasses modalities including cancer vaccines, CAR T-cell therapy, cytokine therapy, gene therapy, monoclonal antibodies, and oncolytic viral therapy, with monoclonal antibodies further divided into chimeric, human, humanized, and murine formats, each presenting distinct development considerations and clinical niches. These modality distinctions influence regulatory complexity, manufacturing footprints, and the clinical evidence required to support broad adoption.

Based on application, biologics address a spectrum of tumor types, notably breast cancer, colorectal cancer, hematologic malignancies, melanoma, non-small cell lung cancer, and prostate cancer. Each indication has unique patient pathways and standard-of-care backdrops that shape trial design and commercial access strategies. Based on administration route, products are delivered intramuscularly, intravenously, orally, or subcutaneously, which affects patient experience, site-of-care selection, and distribution logistics. These choices, in turn, shape commercialization playbooks and patient adherence considerations.

Based on end user, the clinical ecosystem spans ambulatory care centers, home healthcare, hospitals, research laboratories, and specialty clinics, and each setting imposes different infrastructure and training requirements. Finally, based on distribution channel, therapies move through direct sales, hospital pharmacies, online pharmacies, and retail pharmacies, which dictates go-to-market models and patient support infrastructure. Understanding how these segmentation axes intersect allows leaders to prioritize investments in clinical operations, supply chain design, and stakeholder engagement that are most relevant to their specific modality and therapeutic area.

Comparing regional innovation ecosystems, regulatory pathways, and access drivers across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform market entry decisions

Regional dynamics continue to shape where innovation is pursued, how products are manufactured, and the patient access pathways that matter most. In the Americas, robust clinical trial ecosystems, a mature biotech investor base, and established reimbursement frameworks create an environment that supports rapid clinical translation and payer negotiation. However, fragmentation across payers and variability in regional formularies require sponsors to design evidence strategies that address diverse coverage criteria and health economics expectations.

In Europe, the Middle East & Africa region, regulatory harmonization and centralized pathways coexist with country-level access heterogeneity. This mix necessitates tailored regulatory strategies and differentiated value dossiers that reflect local clinical practice and health system priorities. Emerging markets within the region present growing patient populations and unique unmet medical needs, but they also demand pragmatic pricing and distribution approaches that account for infrastructure constraints.

Across Asia-Pacific, governments are increasingly prioritizing domestic biopharmaceutical capability, investing in manufacturing capacity and regulatory modernization. These shifts are encouraging partnerships between multinational developers and regional manufacturers, and they are enabling accelerated approvals for therapies that address high-burden indications. Collectively, regional forces underscore the importance of adaptive market entry strategies that balance global platform advantages with nuanced local execution and stakeholder engagement.

Distilling corporate strategies and partnership dynamics that drive capability building, manufacturing expansion, and portfolio differentiation in biological oncology

Corporate behavior in the biological therapy space reflects a mix of specialization, collaboration, and strategic consolidation. Large pharmaceutical companies are increasingly partnering with nimble biotechnology firms to access cutting-edge platforms while leveraging their own strengths in development scale-up and global commercialization. Contract development and manufacturing organizations play a central role in enabling modality-specific scale, and many have expanded capabilities to support cell and gene therapy workflows, analytical testing, and cold-chain logistics.

At the same time, mid-sized and emerging companies are differentiating through niche scientific platforms, targeted indications, and novel delivery formats. These firms often pursue strategic partnerships with academic centers and clinical networks to access patient populations and translational expertise. Strategic alliances and licensing agreements remain prolific as companies seek to accelerate clinical timelines without shouldering all development risk internally. Mergers and acquisitions are typically motivated by the desire to acquire platform capabilities, expand manufacturing capacity, or secure late-stage assets that complement existing portfolios.

Investor interest remains focused on proven translational pathways and on companies that demonstrate operational readiness to scale. As a result, firms that can present integrated plans for evidence generation, manufacturing, and commercialization tend to command strategic attention from partners and acquirers alike. Overall, corporate strategies emphasize operational resilience, flexible manufacturing models, and the capacity to generate robust clinical and economic evidence.

Actionable strategic moves for developers and manufacturers to fortify pipelines, scale manufacturing, and secure reimbursement pathways in a rapidly evolving oncology ecosystem

Industry leaders should pursue a set of pragmatic actions to strengthen development pipelines, operational readiness, and market access outcomes. First, prioritize platform robustness and process standardization early in development to ease later-stage scale-up, regulatory submissions, and technology transfers. Investing in modular manufacturing and validated supply chains will reduce time to patient and allow more flexible responses to demand fluctuations. Second, embed health economics and outcomes research into clinical programs so that evidence for durability and real-world benefit informs payer discussions from initial dossier development through launch.

Third, accelerate partnerships across academia, clinical networks, and contract manufacturing organizations to share risk and to access specialized capabilities rapidly. Strategic alliances should be structured to include clear milestone-based governance and data-sharing agreements that protect intellectual property while enabling translational progress. Fourth, develop patient-centric service models that simplify administration and follow-up, such as bridging hub services, decentralized trial elements, and remote monitoring, which can improve adherence and support long-term outcome collection. Finally, engage proactively with regulators and trade authorities to anticipate policy changes, advocate for clarity on cross-border flows, and seek pathways that preserve timely patient access while maintaining safety and quality standards.

Explaining the integrated primary and secondary research approach, validation processes, and limitations that ensure the report's strategic reliability and context awareness

The research underpinning this executive summary integrates primary qualitative engagement with industry experts, clinical investigators, manufacturing specialists, and payer advisors together with systematic secondary review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures. Primary inputs were obtained through structured interviews designed to validate operational assumptions, clarify regulatory interpretation, and surface practical case examples of manufacturing and commercialization strategies. Secondary sources were selected for relevance and recency to ensure alignment with current scientific and policy developments.

Data triangulation was applied to reconcile differing perspectives and to identify consistent themes across stakeholders. Where possible, clinical outcomes and regulatory precedents were corroborated against publicly available trial records and approval documentation. Limitations of this approach include potential selection bias inherent in expert interviews and the constantly shifting nature of policy and clinical evidence, which means that readers should treat the findings as a strategic synthesis rather than an immutable prediction. To mitigate these constraints, the research emphasizes transparent assumptions and recommends periodic updates to reflect new approvals, guideline changes, and material policy shifts.

Summarizing the strategic takeaways that integrate scientific potential, operational readiness, and stakeholder alignment to accelerate patient access and program sustainability

In conclusion, cancer biological therapy stands at an inflection point where scientific promise is increasingly matched by operational capability, yet persistent challenges remain in supply chain resilience, regulatory alignment, and payer acceptance. By synthesizing recent technological advances, manufacturing trends, and policy developments, this executive summary identifies clear priorities for stakeholders seeking to translate scientific breakthroughs into accessible therapies.

Leaders that align platform development with scalable manufacturing, invest in evidence generation that addresses payer needs, and adopt flexible market entry strategies across regions will be better positioned to convert clinical success into durable patient access. Continued collaboration across industry, regulators, and clinical communities will be essential to navigate tariff-driven supply chain adjustments and to sustain momentum toward improved outcomes for patients with cancer. The combined focus on operational readiness, strategic partnerships, and patient-centered commercialization will determine which programs realize their full clinical and societal potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of personalized neoantigen vaccines leveraging patient-specific tumor profiles for improved immune response
  • 5.2. Rapid clinical adoption of gene-edited CAR-T therapies with optimized safety switches to minimize cytokine release syndrome
  • 5.3. Expansion of oncolytic virus platforms combined with immune checkpoint inhibitors for synergistic tumor eradication
  • 5.4. Advancements in multispecific antibody formats targeting immune checkpoint and costimulatory pathways for enhanced efficacy
  • 5.5. Integration of AI-driven biomarker discovery to predict patient response to cancer biologics and accelerate development timelines
  • 5.6. Growing interest in microbial-derived immunomodulators to reshape the tumor microenvironment and boost therapy response rates
  • 5.7. Emerging off-the-shelf allogeneic NK cell therapies engineered for persistent activity and reduced graft-versus-host risks
  • 5.8. Development of bispecific T-cell engagers with controlled half-life extensions for improved safety and dosing flexibility

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biological Therapy Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. CAR T-Cell Therapy
  • 8.3. Cytokine Therapy
  • 8.4. Gene Therapy
  • 8.5. Monoclonal Antibodies
    • 8.5.1. Chimeric
    • 8.5.2. Human
    • 8.5.3. Humanized
    • 8.5.4. Murine
  • 8.6. Oncolytic Viral Therapy

9. Cancer Biological Therapy Market, by Application

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Hematologic Malignancies
  • 9.4. Melanoma
  • 9.5. Non-Small Cell Lung Cancer
  • 9.6. Prostate Cancer

10. Cancer Biological Therapy Market, by Administration Route

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Subcutaneous

11. Cancer Biological Therapy Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Laboratories
  • 11.5. Specialty Clinics

12. Cancer Biological Therapy Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Cancer Biological Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Biological Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Biological Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Merck & Co. Inc
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Novartis International AG
    • 16.3.5. Amgen Inc
    • 16.3.6. Pfizer Inc
    • 16.3.7. Johnson & Johnson
    • 16.3.8. AstraZeneca plc
    • 16.3.9. Gilead Sciences, Inc
    • 16.3.10. AbbVie Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY